RE:RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT) I agree the goal is to have multiple shots at goal. However, what I'm saying as an investor is we should not overshoot the runway with stacked up clinical trials that we thus far would need to dilute like drunken monkey's to facilitate in a proper way. GH Research has but two avenues with it's DMT program. You don't need umpteen avenues at the same time to realize a billion dollar market cap. All I'm saying is let's not dilute the company like crazy right after we've gone through a massive consolation of shares. It's my hope people understand we don't have an unlimited runway for dilution. Shareholders of pre split shares need to see a significant increase in share price to get back to even. I continue to put a minimum of 30 $ USD on the table as a break even point for the majority and 60 $ USD for investors like me who retain shares from the 1st reverse split orchestrated by management in 2019. Enough is enough with drunken sailor dilution for pilot studies and/or clinical trials that have no real chance at success. Chronic Cough was the best preclinical trial data we had in the pipeline (110% better than the next competitor) and we haphazardly buried that data halfway around the world in Australia! We might as well wait it out another year before jumping back on that dead horse with a standalone clinical trial. Bellus Health has taken all the shine and management may as well keep playing second fiddle to see how their Phase 3 turns out. If it bombs out, Algernon will then become the only focus in the Chronic Cough arena. If management begins diluting again like they have a clean slate of credit we are screwed again. Those toxic financing deals (share + warrant) will seal our fate by chasing after a 100's of dollars' stock prices just to break even. It's all math and the numbers matter for pre split shareholders versus fresh eyes just looking at the company not understanding or having gone through the hell shareholders have to get where we are now. Moreau consolidated the shares based on an uplist to Nasdaq. We need that to happen ASAP and not be just another notched failure on the Totem pole. We need total concentration on the fundamentals moving forward >>>
Take a look at this “Peer” review comparison @ Stockhouse. See Bellus Health as Algernon’s #1 competitor for Chronic Cough and Mindmed as Algernon’s #1 competitor for psychedelic drugs. Those are Canadian stock comparisons. The USA comparison for Algernon is GH Research with DMT. So looking at the chart it’s insane to think or believe Algernon should be that far back in the pack given the diverse portfolio coming out of the pipeline in 2022.
It’s time to align Algernon with shareholders that value the platform beyond the pennies shareholders have focused on over the years. Management has not helped with quashing the penny flipper mindset given it’s immoral alignment with Kulwant Malhi. However, that relationship is said to have ended. We shall see along with everything else that remains on Algernon’s plate to get done this year. Let’s finally get after it after 3 years of BSing with pilot studies and palling around with a penny world snake in the grass unabashedly biting us in the @ss-ets!